Industry news that matters to you.  Learn more

Biocartis and Amgen Sign a RAS Biomarker Testing Collaboration in Europe

Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), recently announced the signing of a new collaboration agreement with Amgen, a leading biotechnology company. The new agreement, which builds on the existing collaboration between both companies announced on 3 February 20161, aims at accelerating access to RAS biomarker information in up to 10 European countries.

Biocartis and Merck to Collaborate on New Liquid Biopsy Technology for RAS Biomarker Testing

Biocartis, an innovative molecular diagnostics company, recently announced that Biocartis has signed a collaboration agreement with Merck KGaA (Merck) for the development and commercialization of a new liquid biopsy RAS biomarker test for patients with metastatic colorectal cancer (mCRC). The test will be developed on Biocartis’ innovative, fully automated molecular diagnostics system, Idylla™, which is designed to offer accurate and reliable molecular information from virtually any biological sample in virtually any setting. The new test aims to support clinical practice in performing integrated liquid biopsy RAS biomarker tests, independently of the laboratories’ volume of testing or level of expertise.

Biocartis and VIB Join Forces to Develop Unique Diagnostic Cancer Test

Biocartis and VIB recently announced their exclusive license agreement on a novel panel of microsatellite instability (MSI) biomarkers for several cancers, in particular colorectal cancer (CRC). This agreement will enable Biocartis to develop a unique and user-friendly assay, whereby MSI biomarkers can simply and rapidly be detected by Biocartis’ molecular diagnostics platform Idylla™.

Biocartis and Hospital del Mar Join Forces to Develop Diagnostic Colon Cancer Test

Recently Biocartis and Hospital del Mar announced their licence agreement on the EGFR biomarker for colon cancer.

Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform

Biocartis has launched its revolutionary detection platform, Dynamic Multi-Analyte Technology (“DMAT”), a proteomic and nucleic acid platform that provides ultra-high quality data analysis even at higher multiplex formats. The platform launched well ahead of plan and Biocartis has flipped from a late-stage development company into a commercial business.